Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019

(2020) Markus J. Riemenschneider et al.   CLINICAL NEUROPATHOLOGY

Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification

(2019) Anna Wenger et al.   NEURO-ONCOLOGY

MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?

(2018) Shinji Yamashita et al.   JOURNAL OF NEUROSURGERY

Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma

(2018) Masaki Yoshioka et al.   Oncotarget

Quantitative polymerase chain reaction-based detection of HPV 16 E6 and E7 DNA in oral squamous cell carcinoma

(2018) Smitha Thammaiah et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas

(2018) Rui-Chao Chai et al.   MODERN PATHOLOGY

Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma

(2016) Giovanni Brigliadori et al.   JOURNAL OF NEURO-ONCOLOGY

Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma

(2016) Nicole R. Parker et al.   Scientific Reports

Digital PCR quantification ofMGMTmethylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer

(2015) L. Barault et al.   ANNALS OF ONCOLOGY

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

(2015) Michal Bienkowski et al.   CLINICAL NEUROPATHOLOGY

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma

(2013) Matthias Preusser et al.   CLINICAL NEUROPATHOLOGY

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

(2012) Arne Christians et al.   PLoS One

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

(2011) Deborah S. Malley et al.   ACTA NEUROPATHOLOGICA

An extent of resection threshold for newly diagnosed glioblastomas

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers

(2010) Michael Jansen et al.   LANCET NEUROLOGY

Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients

(2010) C.-K. Park et al.   NEURO-ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer

(2009) I Ibanez de Caceres et al.   ONCOGENE

Advantages and limitations of quantitative PCR (Q-PCR)-based approaches in microbial ecology

(2008) Cindy J. Smith et al.   FEMS MICROBIOLOGY ECOLOGY